

- 1 -

SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with  
Kallikrein 2 (KLK2)

<130> BHC 04 01 020

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 786

<212> DNA

<213> Homo sapiens

<400> 1

atgtgggacc	tggttctctc	catcgcccttg	tctgtggggt	gcactggtgc	cgtgccctc	60
atccagtctc	ggattgtggg	aggctggag	tgtgagaagc	atccccacc	ctggcaggtg	120
gctgtgtaca	gtcatggatg	ggcacactgt	gggggtgtcc	tggtgcaccc	ccagtgggtg	180
ctcacagctg	cccattgcct	aaagaagaat	agccaggtct	ggctgggtcg	gcacaacctg	240
tttgagcctg	aagacacagg	ccagagggtc	cctgtcagcc	acagttcccc	acacccgctc	300
tacaatatga	gccttctgaa	gcatcaaagc	cttagaccag	atgaagactc	cagccatgac	360
ctcatgctgc	tccgcctgtc	agagcctgcc	aagatcacag	atgttgtgaa	gttcctgggc	420
ctgcccaccc	aggagccagc	actggggacc	acctgtacg	cctcaggctg	gggcagcata	480
gaaccagagg	agttcttgcg	ccccaggagt	cttcagtgtg	tgagcctcca	tatccatgtcc	540
aatgacatgt	gtgctagagc	ttactctgag	aaggtgacag	agttcatgtt	gtgtgctggg	600
ctctggacag	gtggtaaaga	cacttgtggg	ggtgattctg	ggggtccact	tgtctgtaat	660
ggggtgcttc	aaggtatcac	atcatggggc	cctgagccat	gtgccctgcc	tgaaaagcct	720
gctgtgtaca	ccaagggttgt	gcattaccgg	aagtggatca	aggacaccat	cgcagccaac	780
ccctga						786

<210> 2

<211> 261

<212> PRT

<213> Homo sapiens

<400> 2

Met Trp Asp Leu Val Leu Ser Ile Ala Leu Ser Val Gly Cys Thr Gly

1 5 10 15

Ala Val Pro Leu Ile Gln Ser Arg Ile Val Gly Gly Trp Glu Cys Glu

20 25 30

- 2 -

Lys His Ser Gln Pro Trp Gln Val Ala Val Tyr Ser His Gly Trp Ala  
 35                          40                          45  
 His Cys Gly Gly Val Leu Val His Pro Gln Trp Val Leu Thr Ala Ala  
 50                          55                          60  
 His Cys Leu Lys Lys Asn Ser Gln Val Trp Leu Gly Arg His Asn Leu  
 65                          70                          75                          80  
 Phe Glu Pro Glu Asp Thr Gly Gln Arg Val Pro Val Ser His Ser Phe  
 85                          90                          95  
 Pro His Pro Leu Tyr Asn Met Ser Leu Leu Lys His Gln Ser Leu Arg  
 100                         105                         110  
 Pro Asp Glu Asp Ser Ser His Asp Leu Met Leu Leu Arg Leu Ser Glu  
 115                         120                         125  
 Pro Ala Lys Ile Thr Asp Val Val Lys Val Leu Gly Leu Pro Thr Gln  
 130                         135                         140  
 Glu Pro Ala Leu Gly Thr Thr Cys Tyr Ala Ser Gly Trp Gly Ser Ile  
 145                         150                         155                         160  
 Glu Pro Glu Glu Phe Leu Arg Pro Arg Ser Leu Gln Cys Val Ser Leu  
 165                         170                         175  
 His Leu Leu Ser Asn Asp Met Cys Ala Arg Ala Tyr Ser Glu Lys Val  
 180                         185                         190  
 Thr Glu Phe Met Leu Cys Ala Gly Leu Trp Thr Gly Gly Lys Asp Thr  
 195                         200                         205  
 Cys Gly Gly Asp Ser Gly Gly Pro Leu Val Cys Asn Gly Val Leu Gln  
 210                         215                         220  
 Gly Ile Thr Ser Trp Gly Pro Glu Pro Cys Ala Leu Pro Glu Lys Pro  
 225                         230                         235                         240  
 Ala Val Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys Asp Thr  
 245                         250                         255  
 Ile Ala Ala Asn Pro  
 260

<210> 3  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>  
<223> forward primer

<400> 3  
ctgaagacac aggccagagg

20

<210> 4  
<211> 20  
<212> DNA

- 3 -

<213> artificial sequence

<220>

<223> reverse primer

<400> 4

atgaggtcat ggctggagtc

20

<210> 5

<211> 23

<212> DNA

<213> artificial sequence

<220>

<223> probe

<400> 5

cacctgtcagc cacagcttcc cac

23